Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno

Vargas, C; Espinoza, MA; Giglio, A; Soza, A

Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno

Vargas, C

Espinoza, MA Giglio, A Soza, A

Permalink

Publication Type:: Journal Article
Citation:: Value in Health Regional Issues, 2017, 14 pp. 28 - 32
Issue Date:: 2017-12-01

Closed Access

	Filename	Description	Size
	1-s2.0-S221210991730016X-main.pdf	Published Version	755.16 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Vargas, C https://orcid.org/0000-0002-8667-1926	en_US
dc.contributor.author	Espinoza, MA	en_US
dc.contributor.author	Giglio, A	en_US
dc.contributor.author	Soza, A	en_US
dc.date.available	2017-03-01	en_US
dc.date.issued	2017-12-01	en_US
dc.identifier.citation	Value in Health Regional Issues, 2017, 14 pp. 28 - 32	en_US
dc.identifier.issn	2212-1099	en_US
dc.identifier.uri	http://hdl.handle.net/10453/124218
dc.description.abstract	© 2017 Objectives To assess the impact on the 2015 national health budget of incorporating Daclatasvir/Asunaprevir (DCV / ASV) for the treatment of Hepatitis C genotype 1b (HC1b) in Chile. Methods A Chilean HC1b patients cohort was modelled using local prevalence and incidence data. Two scenarios were built and compared, one were all patients receive Peginterferon/Ribavirin (PR) and another were all patients are treated with DCV/ASV. The analysis was conducted from the perspective of public health system of Chile assuming 100% reimbursement and a time horizon of 5 years. Costs associated with drug treatment, adverse events, other relevant resources and costs associated with disease complications were used. Results At a total DCV/ASV treatment price of USD $55,039, an additional of USD $65,6MM are required during the first year (prevalent cases) equivalent to 0.71% of the 2015 national health budget. From year 2 (incident cases), an additional of USD $12,3MM are needed (0.13% of the 2015 health budget). A price reduction of 33% (USD $36,693), requires an additional of USD $38,2MM the first year and USD $7,16MM from the second year (0.11% and 0.6% of the health budget). If the treatment price is reduced further (USD $18,347), an additional USD $10,9MM are required for the first year and USD $2,03MM from the second year (0.3% and 0.057% of the 2015 heath budget). Conclusion The impact on the health budget ranges between 0.3% and 0.71% the first year and decreases to less than 0.15% from the second year considering the price assessed price range.	en_US
dc.relation.ispartof	Value in Health Regional Issues	en_US
dc.relation.isbasedon	10.1016/j.vhri.2017.03.005	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Hepacivirus	en_US
dc.subject.mesh	Hepatitis C, Chronic	en_US
dc.subject.mesh	Polyethylene Glycols	en_US
dc.subject.mesh	Sulfonamides	en_US
dc.subject.mesh	Imidazoles	en_US
dc.subject.mesh	Isoquinolines	en_US
dc.subject.mesh	Interferon-alpha	en_US
dc.subject.mesh	Recombinant Proteins	en_US
dc.subject.mesh	Ribavirin	en_US
dc.subject.mesh	Protease Inhibitors	en_US
dc.subject.mesh	Antiviral Agents	en_US
dc.subject.mesh	Drug Therapy, Combination	en_US
dc.subject.mesh	Cohort Studies	en_US
dc.subject.mesh	Public Health	en_US
dc.subject.mesh	Genotype	en_US
dc.subject.mesh	Cost-Benefit Analysis	en_US
dc.subject.mesh	Chile	en_US
dc.title	Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno	en_US
dc.type	Journal Article
utslib.citation.volume	14	en_US
utslib.for	140208 Health Economics	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
utslib.for	1117 Public Health and Health Services	en_US
utslib.for	1402 Applied Economics	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Business
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US
pubs.volume	14	en_US

Abstract:

© 2017 Objectives To assess the impact on the 2015 national health budget of incorporating Daclatasvir/Asunaprevir (DCV / ASV) for the treatment of Hepatitis C genotype 1b (HC1b) in Chile. Methods A Chilean HC1b patients cohort was modelled using local prevalence and incidence data. Two scenarios were built and compared, one were all patients receive Peginterferon/Ribavirin (PR) and another were all patients are treated with DCV/ASV. The analysis was conducted from the perspective of public health system of Chile assuming 100% reimbursement and a time horizon of 5 years. Costs associated with drug treatment, adverse events, other relevant resources and costs associated with disease complications were used. Results At a total DCV/ASV treatment price of USD $55,039, an additional of USD $65,6MM are required during the first year (prevalent cases) equivalent to 0.71% of the 2015 national health budget. From year 2 (incident cases), an additional of USD $12,3MM are needed (0.13% of the 2015 health budget). A price reduction of 33% (USD $36,693), requires an additional of USD $38,2MM the first year and USD $7,16MM from the second year (0.11% and 0.6% of the health budget). If the treatment price is reduced further (USD $18,347), an additional USD $10,9MM are required for the first year and USD $2,03MM from the second year (0.3% and 0.057% of the 2015 heath budget). Conclusion The impact on the health budget ranges between 0.3% and 0.71% the first year and decreases to less than 0.15% from the second year considering the price assessed price range.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/124218